Short answer: Corporate healthcare expansion has changed who buys Texas medical practices, how those buyers value them, and what the deal actually pays out. Hospital systems, health insurers, and private equity backed platforms now own the majority of physician practices in the country. For a Texas seller, that means a larger pool of well capitalized buyers and often a higher headline price, but also more complex deal structures where a meaningful share of the purchase price depends on what happens after closing.
Key Takeaways
- Roughly 82 percent of US physicians are now employed by hospitals or corporate entities, and Texas has tracked that shift closely in dermatology, ophthalmology, orthopedics, gastroenterology, and anesthesia.
- Texas enforces the corporate practice of medicine doctrine, so private equity healthcare acquisitions here are structured through a management services organization rather than direct ownership of the clinical entity.
- Texas has not adopted a healthcare transaction notification law, which keeps deal timelines shorter here than in states that require attorney general notice before closing.
- Corporate buyers price a practice on a multiple of adjusted EBITDA. Physician buyers price on seller's discretionary earnings. The two methods produce very different numbers for the same practice.
- Private equity backed offers commonly pay 60 to 80 percent in cash at closing, with the balance in rollover equity or an earnout that depends on how the practice performs under new ownership.
- An unsolicited offer is one bidder's opening number, not a market test. A competitive process is the most reliable way to establish what a Texas practice is actually worth.
I have personally managed more than 100 medical practice transitions, and the single biggest shift I have seen over the past decade is not in what practices are worth. It is in who is writing the check and what strings come attached to it. Twenty years ago, the buyer for a solo internal medicine practice in San Antonio was almost always another physician. Today that same practice might field interest from a hospital system, a payer owned group, and a private equity backed management platform in the same month.
That is good news and complicated news at once. This article covers what physician practice consolidation in Texas actually looks like right now, why Texas in particular attracts corporate capital, how corporate buyers price a practice differently than a physician buyer does, and what you should understand before you sign anything.
What Physician Practice Consolidation in Texas Looks Like Today
The national picture sets the frame. According to research from the Physicians Advocacy Institute and Avalere Health, roughly 82 percent of practicing physicians are now employed by hospitals or other corporate entities, and about 64 percent of physician practices are owned by non physician entities. [1] In the most recent two year period studied, corporate entities including insurers, private equity firms, and pharmacy chains acquired more practices than hospitals did.
Texas has followed that curve, and in some specialties it has run ahead of it. A few things make our market particularly active:
- Population growth. The metros keep absorbing new residents, which means predictable patient volume growth that corporate buyers can underwrite with confidence.
- Deep specialty markets. Dermatology, ophthalmology, orthopedics, gastroenterology, anesthesia, and dental have all seen platform building activity across Houston, Dallas, Austin, and San Antonio.
- Large payer owned footprints. Optum's acquisitions of Kelsey-Seybold Clinic in Houston and Healthcare Associates of Texas in the Dallas area are the two most visible examples of an insurer moving directly into physician ownership here.
- Independent orthopedic and musculoskeletal platforms. Several private equity backed groups have used Dallas-Fort Worth practices as anchor investments for statewide rollups.
If you own a practice in one of these lanes, you are very likely already on a list somewhere. Corporate development teams build target maps by specialty and zip code, and they update them constantly.
Why Texas Attracts Corporate Healthcare Buyers
Texas has two regulatory features that shape every corporate deal in the state.
First, the corporate practice of medicine doctrine is alive and well here. Texas prohibits non physicians from owning a medical practice or employing physicians to practice medicine. Corporate buyers do not get around this by ignoring it. They work through a management services organization, or MSO, structure: the clinical entity stays owned by a licensed physician, and the MSO buys the non clinical assets and contracts to manage everything else, from billing and staffing to real estate and technology.
For a seller, this matters enormously. The MSO structure means you are usually selling two things at once through two agreements, and the economics live almost entirely on the MSO side. Understanding how that split is drawn is the difference between a clean exit and a decade of entanglement.
Second, Texas has not adopted a healthcare transaction notification law. Several states now require parties to notify the attorney general before a material healthcare transaction closes. Texas lawmakers introduced bills along those lines and they did not pass the 2025 regular session. As of this writing, Texas remains one of the less restrictive states for closing a healthcare deal, which is precisely why capital keeps flowing here. Bills of this type tend to resurface, so if you are planning a transition several years out, this is worth tracking with your advisors.
Add no state income tax and a favorable business climate, and Texas becomes a natural destination for platform capital.
How Corporate Buyers Value a Practice Differently
This is where most sellers get surprised. A physician buyer and a corporate buyer are not making the same calculation, and they are not even really buying the same asset.
The mechanics of that EBITDA calculation deserve their own study, and I have written about it in detail in how EBITDA is used in medical practice valuations in Texas. The short version is that corporate buyers normalize your earnings by replacing your compensation with a fair market rate for the clinical work you do, then apply a multiple to what is left. If you have been paying yourself everything the practice earns, that math can be unforgiving until it is properly prepared.
A clear eyed medical practice appraisal before you take a single meeting is not optional in this market. It is the only way to know whether the number on a letter of intent is generous or opportunistic.
The Impact of Corporate Healthcare on Medical Practices After the Sale
Sellers focus almost entirely on price. In corporate deals, the terms after closing matter just as much, and there is a growing body of research explaining why.
Peer reviewed work published through the National Library of Medicine documents what tends to follow private equity acquisition in healthcare: increased debt loads, pressure to raise prices, cost cutting, and in some cases bankruptcy. [2] That analysis notes that private equity owned entities accounted for a disproportionate share of healthcare bankruptcies and that dividend recapitalization, in which the acquired entity takes on debt to pay a distribution to its owners, leaves a weaker balance sheet behind. A systematic review published in The BMJ reached a similar conclusion, finding that private equity ownership was associated with higher costs and mixed to negative effects on quality, with no consistently beneficial impacts identified. [3]
I want to be careful here, because these are averages across a large and varied field, and I have watched physicians do very well in private equity deals. Plenty of platforms are run by operators who genuinely improve the practices they acquire. But averages matter when part of your payout is contingent on the acquirer's performance.
Here is the practical translation for a Texas seller:
Rollover equity is a bet on the buyer, not a payment. If 20 percent of your consideration is equity in the platform, you are an investor in that platform's second sale. If the platform carries heavy debt and the market turns, that equity can be worth substantially less than the spreadsheet at signing suggested. It can also be worth considerably more. Both outcomes are real.
Earnouts transfer risk from the buyer to you. An earnout tied to post close EBITDA hands you performance risk over a business you no longer control. If the new owner changes your staffing model, renegotiates your payer contracts, or shifts referral patterns, your earnout moves with decisions you did not make.
Autonomy provisions are worth negotiating in writing. Scheduling templates, panel size, supply choices, and staffing ratios are the things physicians most often tell me they miss after a corporate sale. If something is important to how you practice, it belongs in the agreement rather than in a verbal assurance during diligence.
Restrictive covenants outlive the relationship. Non competes in these deals are typically drafted with a radius and duration built for the platform's protection, not yours. If you intend to keep practicing in your community afterward, this clause deserves as much attention as the price.
This is exactly the territory our pre and post transaction consulting services are built for, because the work does not end when the wire hits.
What Consolidation Means for Independent Practices That Are Not Selling
If you plan to stay independent, corporate expansion still affects you in three concrete ways.
Referral patterns tighten. When a large group in your market is acquired, referrals often begin to route inside the new network. Specialists who relied on that group need to build new relationships quickly.
Recruiting gets harder and more expensive. Corporate employers compete with signing bonuses, loan repayment, and predictable schedules. Independent practices compete on autonomy and equity, which means having a real path to ownership. A well structured buy in or partnership arrangement has become one of the more effective recruiting tools available to independent groups.
Payer leverage shifts. Larger consolidated groups negotiate better commercial rates. A small independent practice does not have that leverage individually, which is part of why independent practice associations and clinically integrated networks have gained traction across Texas.
None of this makes independence unworkable. It does mean that staying independent has become an active strategy rather than a default, and it should be planned with the same rigor as a sale. That planning is the subject of our guide to medical practice succession planning.
If You Are Considering a Sale in This Market
A few things I tell every Texas physician who calls after receiving an unsolicited offer.
Do not negotiate against yourself with a single buyer. An unsolicited approach is not a market test. It is one bidder's opening number, and it is almost always calibrated to what they think you will accept without shopping. Running a competitive process is the most reliable way to establish real value.
Get your financials in order before you are asked for them. Corporate buyers run deep diligence, and disorganized books cost you both price and credibility. Our breakdown of what Texas buyers look for during medical practice due diligence covers what they will request and in what order.
Model the after tax, after earnout outcome, not the headline. A $6 million deal with 30 percent rollover and a two year earnout is not a $6 million deal. Compare offers on the basis of what actually reaches you and when.
Understand what you want your life to look like in three years. The best deal on paper is a bad deal if it requires five more years of clinical work when you wanted two. Buyer type follows from that answer more than from any valuation.
Our team works across Texas including Houston, Dallas, Austin, and San Antonio, and the buyer landscape genuinely differs by metro. Learn more about how we run a medical practice brokerage engagement, or start with our overview of how to sell a medical practice.
Frequently Asked Questions
For practices with clean financials and adjusted EBITDA above roughly $1 million, buyer demand in Texas remains strong across most specialties. Smaller practices generally find better outcomes with physician buyers or through a merger with a larger local group. The right timing depends far more on your practice’s specific profile and your personal timeline than on the market cycle.
Often yes on the headline number, but the comparison is not apples to apples. Private equity backed platforms typically pay a higher gross figure with a portion held back as rollover equity or earnout. Hospital systems more often pay a lower figure with more of it in cash at closing plus an employment agreement. The better deal depends on your risk tolerance and how long you plan to keep working.
Not directly. Texas enforces the corporate practice of medicine doctrine, which prohibits non physicians from owning a medical practice or employing physicians to practice medicine. Corporate buyers instead use a management services organization structure in which a licensed physician retains ownership of the clinical entity while the MSO acquires the business assets and manages operations under a long term services agreement.
Texas does not currently have a healthcare transaction notification or approval requirement. Legislation to create one was introduced and did not pass the 2025 regular session. Federal antitrust review still applies to transactions above the applicable reporting thresholds, and similar state legislation may be reintroduced, so confirm the current status with counsel before you transact.